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Background: In elderly patients affected by metastatic castration-resistant prostate cancer (mCRPC)
chemotherapic treatment may be the choice if one considers not only the chronological age, but also the
clinical status, the functional reserve, and the vulnerability of patients. Several studies have conﬁrmed
the survival beneﬁt of docetaxel and vinorelbine among every class of age. Most CRP elderly patients are
deﬁned as frail, maybe due to comorbidities: these patients, who are unable to be candidates for a
standard treatment, should be candidates for a more tolerable treatment.
Methods: Twenty-six elderly, frail patients were evaluated. The patients were affected by mCRPC and
were receiving chemotherapy with intravenous weekly docetaxel (12 patients) or oral metronomic
vinorelbine (14 patients). Safety and efﬁcacy were investigated evaluating clinical and objective
response and tolerability. The level of patient satisfaction with treatment was assessed through a
questionnaire.
Results: No signiﬁcant difference was found between groups in terms of 6-month progression-free
survival: 57.1% for patients treated with oral metronomic vinorelbine versus 58.3% for patients treated
with docetaxel. Median progression free survival was 8.6 months (95% conﬁdence interval: 7.1
e9.4 months), and 8.2 months (95% conﬁdence interval: 6.9e9.3 months) for patients treated with oral
metronomic vinorelbine and socetaxel, respectively. Oral metronomic vinorelbine was associated with
increased patient satisfaction with respect to docetaxel administration. The most frequent side effect
associated with oral metronomic vinorelbine was anemia and vomiting, with similar frequency
compared to patients treated with docetaxel.
Conclusion: Weekly docetaxel and oral metronomic vinorelbine are equally effective and well tolerated
in elderly unﬁt and frail patients affected by mCRPC. Metronomic vinorelbine treatment is associated
with higher patient compliance and satisfaction.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer represents the most common cancer among
American1 and European men, and it is associated with an age-
adjusted mortality rate of 10.5/100,000 patients, which is still
growing all across Europe.2 Metastatic castration-resistant prostate
cancer (mCRPC) is characterized by disease progression after
medical and/or surgical castration.
Nowadays, aging population is a critical issue due to the
increased number of people aged  80 years. More than 69 million, Via Testaferrata, 1, 96100
ciﬁc Prostate Society, Published bmen in 2000 were aged 80 years, whereas in 1950 the population
counted only 13.8 million men aged  80 years; furthermore, it is
expected to reach 379 million in 2050.3 In addition, scientiﬁc
progress warrants increased life expectancy, so an increase in
prostate cancer in elderly or older patients is expected.4
Chemotherapy is a standard treatment for most of patients
affected by mCRPC. In elderly patients chemotherapy treatment
should be tailored not only to the chronological age, but also to the
clinical status, functional reserve, and vulnerability.5
Age-stratiﬁed analysis of patients (< 65 years,  65 years, and
 75 years) has conﬁrmed the survival beneﬁt of docetaxel among
every class of age6; therefore, administration of docetaxel 75 mg/
m2 every 3 weeks when indicated should be considered as the
standard chemotherapy treatment of prostate cancer, independent
from age.y Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Prostate Int 4 (2016) 15e1916Several data have shown the safety and efﬁcacy of vinorelbine in
the treatment of elderly patients with mCRPC.7,8 Most of these
studies have been implemented when the oral formulation of
vinorelbine has been available in order to exploit the easiest route
of administration compared with intravenous drugs and evaluated
the patients preferences of administration.9
Most of the CRP elderly patients are deﬁned as frail, maybe due
to comorbidities. These patients, who are unable to be candidates
for a standard treatment, should be candidates for a more tolerable
treatment.
The weekly docetaxel regimen seems to be associated with less
side effects compared with the 3-week regimens.10,11 At the same
time, several studies have demonstrated the efﬁcacy of vinorelbine
in the treatment of advanced cancer,12 especially in elderly patients
with poor performance status where improved safety and
compliance has been shown.13 The intravenous administration of
both vinorelbine and docetaxel as a ﬁrst-line strategy in the
treatment of hormone-refractory prostate cancer (HRPC) has been
compared in previous publications demonstrating the equal efﬁ-
cacy of these two drugs.13 To date, oral versus intravenous
chemotherapy for the treatment of CRPC evaluating quality of life
among elderly, unﬁt patients has not been investigated to date.
Finally, a valid option for the treatment of this population due to
lower toxicity than a maximum tolerated dose regimen is metro-
nomic oral vinorelbine (mVNR); mVNR is administered three times
per week, of a considerably lower dosage than each standard
administration of standard vinorelbine in a maximum tolerated
dose schedule. This schedule is now known to involve multiple
mechanisms of action including an antiangiogenesis effect, mod-
ulation of the immune system, and indirect cytotoxic effect against
cancer cells.14
2. Materials and methods
2.1. Patients
A total of 26 patients were evaluated with an age range of
70e87 years old, with performance status > 1 (Eastern Cooperative
Oncology Group); all of them presented with symptomatic bone
pain andwere considered unﬁt/frail due to fatigue, slowingwalking
speed, and physical activity reduction.15,16 Treatment allocationwas
based only on clinical evaluation.
All patients had a histological conﬁrmed diagnosis of metastatic
prostate cancer, and all had already undergone hormone therapy
with luteinizing hormone-releasing hormone analogous/androgen
deprivation therapy (ADT).
Of those, 12/26 (46.2%) patients were treated with intravenous
weekly docetaxel 30 mg/m2 (schedule 1, 8, 15, 22, 29, q 36); while
14/26 (53.8%) patients were treated with oral mVNR 30 mg 3 days
per week for 3/4 weeks. Both cohorts also received prednisone
5 mg, twice a day (b.i.d.).
Patients were clinically evaluated at baseline and at the begin-
ning of the course, along with prostate-speciﬁc antigen (PSA)
evaluation. Computed tomography or positron emission tomogra-
phy evaluation was executed every 3e4 months. All patients were
followed-up for 18 months.
2.2. Evaluation of frailty
Frailty evaluation is based upon functional criteria.15 It is posi-
tive when three out of the ﬁve of the following items are present:
weight loss (4.5 kg in the past year), self-reported fatigue, hand-
grip reduction, physical activity reduction (evaluated by means of
Physical Activity Scale for the Elderly17), and slowing walking speed
(> 7 s/4.57 m).2.3. Efﬁcacy end-points
Safety and efﬁcacy were investigated evaluating clinical
response as deﬁned by Response Evaluation Criteria in Solid Tu-
mors (RECIST) criteria,18 as symptom control, PSA level variations,
and 6-/12-months progression-free survival (PFS).
Biochemical response was evaluated as follows: complete
response¼ PSA < 4 ng/mL or reduction > 80% from baseline; partial
response ¼ PSA reduction > 50% from baseline; and disease
progression ¼ PSA increase > 50% from baseline; stable
disease ¼ every other condition.
Symptomatic response was evaluated as follows: complete
response¼ performance status 0e1, absence of pain, and analgesics
administration; partial response¼ 2 points reduction in the scale of
analgesics consumption, pain, or performance status, or 1 point
reduction at least in two of the previous dominium; and disease
progression ¼ 2 points reduction in the scale of analgesics con-
sumption, pain, or performance status, or 1 point reduction at least
in two of the previous dominium.
Objective response was evaluated standing on the RECIST
criteria,18 which can be summarized as follows for target lesions:
complete response ¼ disappearance of all target lesions along with
pathologic lymph node(s) diameter reduction (< 10 mm); partial
response ¼  30% reduction of the sum of the diameters of target
lesions from baseline; disease progression ¼  20% increase of the
sum of the diameters of target lesions from the lowest known value
(at baseline or initial response); and stable disease ¼ every other
condition.
Response of nontarget lesions was deﬁned (always accordingly
to RECIST criteria18 as follows: complete response ¼ disappearance
of all nontarget lesions along with pathologic lymph node(s)
diameter reduction (< 10 mm), and biomarkers negativity; disease
progression ¼ increase (number or size) of nontarget lesions;
borderline ¼ one or more nontarget lesion persistent and/or
biomarker positivity.
In addition, every patient was asked to ﬁll out a questionnaire
(at baseline and every 3 months afterwards) in order to ascertain
their degree of satisfaction with the treatment adopted. Possible
answers to the questionnaire were: satisﬁed, unsatisﬁed, and
indifferent; and motivations could be enclosed.
2.4. Safety end-points
Safety of the treatment was evaluated by means of the Common
Toxicity Criteria.19
3. Results
Among the 26 patients with metastatic prostate cancer, the
mean age was 78.1 years. Every patient (26/26) had bone metas-
tases, seven out of 26 (27%) had lymph node involvement, and three
out of 26 (11.5%) had visceral metastases. In addition, nine out of 26
(35%) previously underwent radical prostatectomy, ﬁve out of 26
(20%) radiotherapy, and 26/26 previously received hormonal ther-
apy (luteinizing hormone-releasing hormone analogous, ADT;
Table 1).
3.1. Efﬁcacy evaluation
No signiﬁcant difference was found between groups in terms of
PFS: 57.1% for patients treated with oral mVNR versus 58.3% for
patients treated with docetaxel. Median PFS was 8.6 months (95%
conﬁdence interval: 7.1e9.4 months), and 8.2 months (95% conﬁ-
dence interval: 6.9e9.3 months) for patients treated with oral
mVNR and docetaxel, respectively. Patients still on treatment after
Table 1





Median age (y) 77 ± 5 81 ± 6
Disease staging
Locally advanced 0 (0) 0 (0)
Metastatic 14 (100) 12 (100)
Bone metastases only 9 (69.2) 9 (75)
Bone þ lymph node involvement 4 (30.7) 3 (25)
Bone þ visceral involvement 2 (14.2) 1 (8.3)
Risk evaluation
Very low/low 5 (35.7) 3 (25)
Intermediate 6 (42.8) 7 (58.3)
High 2 (14.2) 2 (16.6)
Very high 1 (7.1) 0 (0)
Treatment of local disease
Surgery 3 (21.4) 6 (50)
Radiotheraphy 2 (14.2) 3 (25)
Hormone therapy only 9 (64.2) 3 (25)
Prechemotherapeutic treatment
LHRH analogous 3 (20.3) 2 (16.6)
ADT 8 (64.8) 9 (75)
Others 3 (14.9) 1 (8.3)
Data are presented as n (%) or mean ± standard deviation.
ADT, androgen deprivation therapy; LHRH, luteinizing hormone-releasing hormone.
Tralongo et al / Treatment of frail with mHRPC 1712 months were four out of 14 (28.5%) among those receiving oral
mVNR, and two out of 12 (16.6%) among those receiving docetaxel.
Clinical and biochemical responses were stable after the ﬁrst
two evaluations, with acceptable pain control and PSA levels in
both groups.
Among patients experiencing disease progression, 87.5% of
those receiving oral mVNR versus 100% of those receiving docetaxel
also showed rising PSA values; 81.2% of those receiving oral mVNR
versus 70.8% of those receiving docetaxel showed clinical pro-
gression as well.
At the 9-month analysis, six out of 14 patients receiving oral
mVNR and ﬁve out of 12 patients receiving docetaxel were still on
treatment. Of those, patients showing an objective positive
response were four out of six (66.6%) with oral mVNR versus two
out of ﬁve (40%) with docetaxel (Table 2).3.2. Patient satisfaction
Oral mVNR was associated with increased patient satisfaction
(11/14 or 78.5%) with respect to docetaxel administration (7 out of
12 or 58.3%) at the 6-month analysis, and at 18 months docetaxel
was associated with reduced patient satisfaction (3 out of 12 orTable 2





3 mo PSA SD: 4 PR: 8 DP:2 SD: 6 PR: 4 DP:2
Clinical SD: 4 PR: 9 DP:1 SD: 7 PR: 3 DP:2
Imaging SD: 4 PR: 8 DP:2 SD: 6 PR: 4 DP:2
6 mo PSA SD: 2 PR: 6 DP:4 SD: 4 PR: 3 DP:3
Clinical SD: 3 PR: 6 DP:3 SD: 5 PR: 3 DP:2
Imaging SD: 3 PR: 5 DP:4 SD: 4 PR: 3 DP:3
9 mo PSA SD: 3 PR: 3 DP:2 SD: 3 PR: 2 DP:2
Clinical SD: 4 PR: 2 DP:2 SD: 4 PR: 2 DP:1
Imaging SD: 3 PR: 3 DP:2 SD: 3 PR: 2 DP:2
12 mo PSA SD: 3 PR: 2 DP:1 SD: 1 PR: 1 DP:3
Clinical SD: 2 PR: 2 DP:2 SD: 2 PR: 1 DP:2
Imaging SD: 3 PR: 1 DP:2 SD: 2 PR: 0 DP:3
DP, disease progression; PR, partial response; PSA, prostatic-speciﬁc antigen; SD,
stable disease.25%). Furthermore, patients disclosed that satisfaction regarding
oral mVNR was due to oral administration and lower perception of
side effects.3.3. Safety evaluation
The most frequent side effect associated with oral mVNR
administration was anemia, with similar frequency compared with
patients treated with docetaxel (8% vs. 7% Grade 3) and vomiting
(5% Grade 3 vs. 2%, respectively). Grade 3 constipationwas recorded
in 5% of patients belonging to the oral mVNR group versus 0% of
those receiving docetaxel. Severe vomiting involved only 5% of
patients treated with metronomic VNB (mVNB). The incidence of
other side effects are reported in Table 3.4. Discussion
This observational study was aimed to investigate safety and
efﬁcacy of chemotherapy with oral mVNR versus intravenous
docetaxel in frail elderly patients with mCRPC.
Elderly patients, are characterized by a progressive decline of
physiologic systems and a consequently decreased functional
reserve capacity, conferring vulnerability or frailty in the presence
of environmental stressors15,16; frail patients, when affected by
metastatic prostate cancer, are not optimally treated.20
Recent studies reported that early chemotherapy, especially in
symptomatic patients with “high volume” disease, insures a sig-
niﬁcant survival beneﬁt.25 Docetaxel treatment is associated with a
10e15% response rate, with a survival prolongation of 1 year, and
with an increased quality of life.10,21
The results of the ChemoHormonal Therapy Versus Androgen
Ablation Randomized Trial for Extensive Disease in Prostate Cancer
(CHAARTED) trial22 have shown a beneﬁt in overall survival of the
docetaxeleADT combination, mainly in patients with high meta-
static extent, in which it had an overall survival of 17 months
compared with ADT alone. The same results were recently reported
in the Systemic Therapy in Advanced or Metastatic Prostate Cancer:
Evaluation of Drug Efﬁcacy (STAMPEDE) multi-arm, multi-stage
trial23 in which the addition of docetaxel to hormonal treatment
showed a survival advantage of 65 months versus 43 months,
(P ¼ 0.002, hazard ratio ¼ 0.73).
In addition, docetaxel administration is also correlated to better
pain control, reduced levels of PSA, and an improvement of quality
of life.
In elderly patients, even if chemotherapy showed a clear beneﬁt
in terms of survival and post-treatment quality of life, it is stillTable 3





WHO grade 1 2 3 4 1 2 3 4
Neutropenia 18 18 12 11 27 24 25 3
Thrombocytopenia 18 12 3 0 26 15 3 1
Anemia 21 12 8 1 22 10 7 2
Nausea 19 26 3 0 11 15 2 0
Vomiting 2 1 5 0 2 1 2 1
Mucositis 12 8 0 0 15 12 2 0
Alopecia 8 10 3 0 15 28 20 0
Constipation 18 24 5 1 7 10 0 0
Neurotoxicity 5 3 0 1 13 18 9 1
Pain 13 5 0 1 11 7 4 1
Fever 8 5 0 1 14 19 4 1
Fatigue 11 9 0 1 28 30 11 3
WHO, World Health Organization.
Prostate Int 4 (2016) 15e1918questioned due the toxicity.5 A recent study from the UK showed
that most prostate cancer patients with advanced age were not
considered suitable for chemotherapy.24
Conversely, most elderly patients wish to be treated as younger
patients seeking the potential survival beneﬁt of chemotherapy
despite the risk of toxicity.25
Indeed, considering the toxicity reported with docetaxel,6,10 a
previous study by Tannock et al10 described a change with different
schedules of administration: every 3 weeks recorded more
frequent G3-4 neutropenia (32% vs. 2%) and alopecia (65% vs. 50%),
while theweekly schedule had registered increased tearing (21% vs.
10%) and epistaxis (17% vs. 6%). Weekly27 or twice per week13,26
administration may represent a choice for elderly unﬁt patients.
The studyof Fossået al27 involved109patients randomlyassigned
to weekly docetaxel associated with prednisone b.i.d or to the latter
alone, biochemical response was signiﬁcantly better among the ﬁrst
groupofpatients (54%vs. 26%). In addition, PFSwas11months versus
4 months, respectively. Overall median survival was 27 months for
patients administered with docetaxel versus 18 months for patients
administered with prednisone alone. In conclusion, pain relief and
quality of life evaluation deﬁnitely demonstrated superiority of the
treatment regimen including docetaxel. Most common adverse ef-
fects associated with the latter medication were neutropenia and
thrombocytopenia; with treatment delay for no more than 2 weeks.
Grade-2 stomatitis and Grade-3 peripheral neuropathy warranted a
dose reduction of weekly Docetaxel (25 mg/m2).
Oral vinorelbine demonstrated to be an attractive alternative
also due to its pharmacokinetic characteristics: rapid absorption
(1.5e3 hours), 40-hour half-life with 40% bioavailability not inﬂu-
enced bymeals, even though nausea and vomiting are less frequent
when medication is taken postprandial; speciﬁcally all those
characteristics are not inﬂuenced by patients' age.
Vinorelbine is a semisynthetic vinca alkaloid with cytotoxic ef-
fect against some different neoplasms. It is a mitotic inhibitor with
better therapeutic index and lower neurotoxicity with respect to
other vinca alkaloids, due to the lower axonal degradation associ-
ated with its use. Use of vinorelbine in the treatment of prostate
cancer, although limited, has been shown to be effective: several
studies7,8,28,29 previously showed clinical response rate and pain
control. Speciﬁcally, clinical response was reported to range be-
tween 20e40% with 20% reduction of PSA levels.7,8,28,29
Furthermore, an Italian study30 investigated the association of
oral vinorelbine (60mg/m2) plus prednisone (5 mg b.i.d.) among 33
elderly and unﬁt patients affected by mCRPC. That paper clearly
showed acceptable safety and efﬁcacy of this treatment with pos-
itive clinical and biochemical responses in about one third of pa-
tients, a median PFS of 13.4 weeks, and an overall median survival
of 45 weeks. Most frequent adverse events involved hematopoiesis.
Aiming to enhance tolerability preserving effectiveness, a
metronomic schedule of oral administration has been previously
validated. It consists of low-doses administered at close intervals, in
order to avoid extended outages from therapy.31 This strategy not
only represents an easy-to-use protocol for the patients, but also
demonstrated satisfactory safety proﬁle and effective results.
Standing on its pharmacokinetic characteristics, vinorelbine results
optimal for oral administration every other day (3 times per week)
even for long periods (3e4 weeks); thus limiting treatment-related
toxicity.32
A recent Greek study12 evaluated different dosages (30 mg,
40 mg, and 50 mg) of oral mVNR in the treatment of some meta-
static solid cancers (breast, prostate, nonsmall cell lung cancer); the
ﬁnal conclusion was that 50 mg dosage (3 times per week) was
associatedwith best responses and acceptable toxicity. The absence
of clinically-relevant toxicity correlated to prolonged and effective
doses of oral mVNR was impressive, indeed blood countssuppression was rare, nonhematological toxicity was negligible,
and peripheral neuropathy was minimal; even in those patients
who were on treatment for some months or years.12
Safety and efﬁcacy of oral mVNR has been studied also in 34
elderly patients with metastatic breast cancer, and complete re-
sponses were seen in 6% of patients, while 32% of patients showed
partial responses; with a median PFS was 7.7 months, and overall
median survival was 15.9 months.32 The protocol was well toler-
ated in all patients whom received at least three cycles of therapy.
Hence, oral mVNR may represent a robust alternative also for pa-
tients with HRPC.
Taking into account that patients included in this experience
were all elderly and frail, reported results appears to be satisfactory,
as shown by 6-month PFS of 58.3% (7 out of 12 patients), and 12-
month PFS of 16.6% (2 out of 6 patients still on treatment after
1 year). Biochemical response (58.3% at 6 months) and pain control
(66.6%) of docetaxel-allocated patients were as well impressive.
Grade-3 neutropenia was the most frequent adverse event associ-
ated with the administration of docetaxel (31%), which anyway did
not prompt a dose reduction.
The intravenous administration was well tolerated by patients,
even though percentage of patient satisfaction was lower in com-
parison with oral vinorelbine (58.3% vs. 78.5%). This result was
mainly correlated to the route of administration.
Most common side effects associated with oral mVNR admin-
istration were nausea, and constipation; of note the incidence of
high grade toxicity was very limited.
All six patients treated with oral mVNR who reached ﬁnal eval-
uation gave satisfactory responses to the questionnaires, muchmore
thanwhat seenamongdocetaxelpatients. Patientopinionwasdriven
mainly by oral administration, and the low incidence of side effects.
Our study, despite its small sample size (26 patients), demon-
strated the noninferiority of oral mVNRwith respect to docetaxel, as
conﬁrmed by similar 6-month PFS. Clinical and biochemical re-
sponses conﬁrmed effectiveness of treatment both at 6-month and
9-month evaluations. After 1 year the percentage of patients
continuing treatmentwas higher among those receiving oralmVNR.
In conclusion, elderly unﬁt and frail patients affected by HRPC,
whom are frequently ruled out from chemotherapy treatment, can
be treated with traditional drugs by means of an alternative
scheduling: weekly docetaxel and oral mVNR are equally effective
and well tolerated; mVNR treatment is associated with higher pa-
tient compliance and satisfaction.
Obviously, further and larger studies are needed to conﬁrm
these ﬁndings. Meanwhile, given the absence of any other experi-
ences in frail patients, oral mVNR or weekly docetaxel should be
considered for the treatment of those patients affected by CRPC
suitable for chemotherapy.Conﬂicts of interest
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